Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 15/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271677 | 0.89 | MCL1 (0.46) | MCL1PSMB5PSMB1LMNA | |
| SCHEMBL5019123 | 0.88 | PSMB5 (0.42) | PSMB5PSMB1PLGPRSS1PRSS2 | |
| SCHEMBL10271674 | 0.83 | MCL1 (0.43) | MCL1PSMB5PSMB1LMNA | |
| SCHEMBL10271675 | 0.83 | MCL1 (0.43) | MCL1PSMB5PSMB1LMNA | |
| SCHEMBL5018619 | 0.80 | PSMB5 (0.42) | PSMB5PSMB1PLGPRSS1PRSS2 | |
| SCHEMBL5019089 | 0.76 | PSMB5 (0.48) | PSMB5PSMB1LMNA | |
| SCHEMBL5018627 | 0.75 | PSMB5 (0.43) | PSMB5PSMB1PLGPRSS1PRSS2 | |
| SCHEMBL5019124 | 0.74 | PSMB5 (0.45) | PSMB5PSMB1LMNA | |
| SCHEMBL5025306 | 0.73 | PSMB5 (0.45) | PSMB5PSMB1 | |
| SCHEMBL5018524 | 0.70 | PSMB5 (0.49) | PSMB5PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010054102-A2 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | MCL1 1271/4885PSMB5 865/4885PSMB1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.